Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

5.0%

2 terminated out of 40 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

58%

7 of 12 completed with results

Key Signals

7 with results86% success

Data Visualizations

Phase Distribution

40Total
Not Applicable (3)
P 1 (36)
P 2 (1)

Trial Status

Recruiting12
Completed12
Not Yet Recruiting6
Unknown6
Terminated2
Active Not Recruiting1

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (40)

Showing 20 of 20 trials
NCT07617727Phase 1RecruitingPrimary

A Phase I Study of JSKN021 in Advanced Solid Tumors

NCT07368127Phase 1RecruitingPrimary

A Study of TPD3310 in Patients With Advanced Malignant Tumors

NCT07639450Phase 1RecruitingPrimary

N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors

NCT06571422Phase 1Active Not RecruitingPrimary

Phase I Study of WJ47156 Monotherarpy and in Combination With Other Therapy in Advanced Solid Tumors

NCT07665970Phase 1Not Yet RecruitingPrimary

SCTB41 Plus SCTB39G With or Without Standard Therapy in Advanced Solid Tumors

NCT07657585Phase 1Not Yet RecruitingPrimary

CIB In Vivo CAR-T Lentiviral Injection in Patients With Advanced Malignant Tumors

NCT07480733Phase 2RecruitingPrimary

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

NCT07612488Phase 1Not Yet Recruiting

A Study of CS231295 in Patients With Advanced Solid Tumors

NCT06573294Phase 1TerminatedPrimary

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

NCT07566247Phase 1Not Yet RecruitingPrimary

A Phase I Clinical Study of AK150 in Advanced Malignant Solid Tumor

NCT06499350Phase 1RecruitingPrimary

A Study of FC084CSA in Combination of Tislelizumab in Patients With Advanced Malignant Solid Tumors

NCT06717750Phase 1RecruitingPrimary

A Study of CSCJC3456 in Patients With Advanced Malignant Tumors

NCT07363369Phase 1Not Yet RecruitingPrimary

Exploratory Clinical Study of FAP mRNA Vaccine in Patients With Advanced Malignant Solid Tumors

NCT07292402Phase 1RecruitingPrimary

JSKN022 in Subjects With Advanced Malignant Solid Tumors

NCT06231550Phase 1CompletedPrimary

A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors

NCT05383703Phase 1CompletedPrimary

Clinical Study of MNC-168 Enteric-coated Capsule in the Treatment of Advanced Intestinal Solid Tumor

NCT05749627Not ApplicableRecruitingPrimary

Using Neoantigen Peptide Vaccine/neoantigen-based DC to Treat Advanced Malignant Solid Tumors

NCT06464055Phase 1RecruitingPrimary

A Study of GQ1010 in Subjects With Advanced Solid Tumors

NCT06728189Phase 1RecruitingPrimary

A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors

NCT04908046Phase 1CompletedPrimary

A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

Scroll to load more

Research Network

Activity Timeline